Treatment of Isolated Internal Mammary Node Metastasis from NSCLC

Rationale for Oligometastatic Approach

The European Society for Medical Oncology recommends treating isolated IMN metastasis from NSCLC as oligometastatic stage IV disease with definitive local therapy combined with systemic platinum-based chemotherapy or targeted therapy based on molecular profile 1, 2
Stage IV NSCLC patients with solitary metastases can be treated with curative intent when the metastatic site is amenable to local therapy, as demonstrated in brain, adrenal, and contralateral lung metastases, according to the European Society for Medical Oncology 1, 2

Complete molecular profiling is mandatory before treatment initiation, including EGFR mutation analysis, ALK rearrangement testing, and PD-L1 expression in all patients with advanced NSCLC, as recommended by the National Comprehensive Cancer Network 4, 5
Comprehensive staging with PET-CT scan is essential to confirm truly isolated disease and exclude other metastatic sites, according to the National Comprehensive Cancer Network 4, 6
Brain MRI should be performed to rule out occult CNS metastases, as neuroimaging is more sensitive than CT for detecting brain involvement, as recommended by the European Society for Medical Oncology 4

Surgical resection of the IMN may be considered in highly selected cases where complete R0 resection is technically feasible, though this is rarely performed for IMN specifically, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 7, 1

For patients with actionable molecular alterations, first-line targeted therapy is preferred over chemotherapy for EGFR mutations, ALK rearrangements, and other actionable drivers, as these yield higher response rates, according to the National Comprehensive Cancer Network 5
Platinum-based doublet chemotherapy is the standard for patients without actionable molecular alterations, using regimens such as carboplatin/paclitaxel, cisplatin/pemetrexed, or cisplatin/vinorelbine, as recommended by the European Society for Medical Oncology 4, 2

If systemic therapy is urgently needed, initiate platinum-based chemotherapy first, then deliver SBRT to the IMN after 2-3 cycles, according to the National Comprehensive Cancer Network 5
Limit platinum-based chemotherapy to 4-6 cycles maximum, with response evaluation after 2-3 cycles using CT imaging, as recommended by the European Society for Medical Oncology 4, 2

Do not assume IMN involvement is N2 disease requiring chemoradiation: Isolated IMN metastasis represents distant (M1) disease, not locoregional nodal disease, and should be staged as M1a, according to the European Society for Medical Oncology 4
Ensure adequate tissue for molecular testing: Re-biopsy of the IMN may be necessary if the primary tumor tissue is insufficient or outdated for comprehensive molecular profiling, as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 4, 5

Close follow-up every 6 weeks initially is recommended to allow early detection of progression and timely initiation of second-line therapy, according to the European Society for Medical Oncology 1